quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 10, 2026

INVESTOR NOTICE: Hercules Capital (HTGC) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action– Hagens Berman

View original at globenewswire.com
INVESTOR NOTICE: Hercules Capital (HTGC) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action– Hagens Berman SAN FRANCISCO, April 10, 2026 (GLOBE NEWSWIRE) -- Hercules Capital (NYSE: HTGC) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise a…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Hercules has assured investors about the robust origination process for sourcing potential investments and the effectiveness of its due diligence process prior to underwriting its investments

    60% confidence
  • As a result of overstated due diligence and misclassified portfolio investments, Hercules overstated or misrepresented its portfolio valuations and its net asset value (NAV)

    60% confidence
  • We're investigating Hunterbrook's allegations and, if true, whether Hercules misled investors about its sourcing, underwriting, marks, PIKs, and, ultimately its NAV

    60% confidence
  • About 35% of the value of Hercules' loan portfolio is software-exposed, and despite billions worth of such debt across the industry falling into distressed territory, Hercules still marks its software book at 100 cents on the dollar

    60% confidence
  • A former member of Hercules' finance team provided information raising flags about the company's valuation process because, unlike other BDCs, the team was small and overstretched with few checks in place

    60% confidence
  • A growing share of Hercules' income is 'phantom' because of the company's increasing usage of payment-in-kind (PIK) loans to enable its borrowers to pay interest by adding to the principal of their debt rather than paying interest on their debt

    60% confidence
  • According to a former Hercules analyst who worked on deal sourcing, the company's deal sourcing process essentially amounted to 'go on the website for Google Ventures and just see what they invest in and just copy it'

    60% confidence
  • The complaint alleges that Hercules overstated the due diligence with which it conducted its deal sourcing and loan origination process, overstated the due diligence with which it conducted its portfolio valuation process, and reported misclassified portfolio investments

    60% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com